[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,411,0,25,[9,46,70,100,123,146,171,200,229,257,283,305,334,357,383,411,433,454,478,505,525,564,584,608,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054326","dose-response-effects-of-a-brief-audio-guided-mindfulness-intervention-for-acute-pain-100054326",false,"NCT07562412","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain While Awaiting Orthopedic Care","Inclusion Criteria:\n\n* Receiving treatment at Tallahassee Orthopedic Center\n* Understanding English instructions fluently\n* Being 18 years of age or older\n\nExclusion Criteria:\n\n* Unable to consent because of physical or mental incapacity.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project is a single-site, three-arm, randomized controlled trial investigating whether different length audio-recorded mindfulness practices differentially decrease pain among patients in a waiting room awaiting orthopedic care.",[27,28,29,30,31,32],"Pain","Pain Management","Mindfulness","Orthopedic","Acute Pain","Chronic Pain","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-04-29",{"date":41,"type":21},"2027-04-30",{"name":43,"class":44},"Florida State University","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100499762","state-of-hormones-impact-nociceptive-expression-100499762","NCT05787470","State of Hormones Impact Nociceptive Expression","SHINE","Inclusion Criteria:\n\n* self-identification as one of the above gender identities\n* understanding of verbal and written English.\n* participants that have been on\u002Foff hormone treatment for at least 6 months\n\nExclusion Criteria:\n\n* pain in at least 3\u002F7 days\u002Fweek for the past 3 months\n* HIV positive diagnosis\n* cardiovascular or pulmonary disease\n* regular use of opioid pain medications\n* uncontrolled hypertension (i.e. SBP\u002FDBP of \\> 150\u002F95)\n* current illness accompanied by fever (body temperature \\>38 °C)\n* prostatectomy, hysterectomy or oophorectomy\n* hospitalization due to psychiatric illness within the last 6 months.",true,"65 Years",{"count":56,"type":21},120,"OBSERVATIONAL","The Investigators have recently published on differences in pain sensitivity measures between cis and trans individuals in the local area. The investigators observed the anticipated differences in pain sensitivity between CM and CW (CW \\> CM), but found that the TW were phenotypically similar to CW in all measures. However, the investigators did not assess hormone level, nor did the investigators recruit TM participants. Here, with the assistance of two local community group stakeholders the investigators will recruit the following groups: CM, CW, TM+T (currently taking exogenous testosterone), TW+E (exogenous estradiol), TM, and TW (n=20\u002Fgroup). The investigators will use quantitative sensory testing to assess sensitivity to cold, pressure, and heat via standardized protocols. Blood samples will be taken for assessment of stress and reproductive hormone levels, immune cell populations and stimulated cytokine release. Finally, questionnaires will measure pain state, quality of life (QOL), voice QOL, body image, appearance, self-reported health, masculinity\u002Ffemininity, community connectedness, gender role, sleep, depression, social support, adverse childhood experiences and stigma.",[27,60],"Gender Identity","2026-07-01",{"date":63,"type":37},"2026-07-02",{"date":65,"type":37},"2023-03-01",{"date":67,"type":21},"2027-07-31",{"name":69,"class":44},"University of Alabama at Birmingham",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":53,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100643426","virtual-reality-for-pain-and-anxiety-in-pediatric-dental-treatment-100643426","NCT07636330","Virtual Reality for Pain and Anxiety in Pediatric Dental Treatment","Effects of Immersive Virtual Reality on Pain, Anxiety, and Post-Procedural Experience in Pediatric Dental Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 6 to 12 years\n* Scheduled for a routine invasive dental procedure\n* Accompanied by a parent or legal guardian\n* Parent\u002Fguardian able to provide written informed consent\n\nExclusion Criteria:\n\n* Children with visual or hearing impairments that would prevent use of the VR headset\n* Children with a history of motion sickness\n* Children with severe cognitive or developmental delays that would prevent completion of study measures\n* Children who have previously participated in this study\n* Children requiring emergency dental treatment","6 Years","12 Years",{"count":80,"type":21},80,[24],"The goal of this clinical trial is to learn whether immersive virtual reality (VR) reduces pain and anxiety in children aged 6-12 years during routine dental procedures. The main questions it aims to answer are:\n\n* Does VR distraction reduce self-reported pain and anxiety during dental treatment compared to standard behaviour guidance?\n* Does VR distraction improve children's post-procedural experience and willingness to return for future dental visits?\n\nResearchers will compare children using a VR headset during dental treatment to children receiving standard behaviour guidance techniques.\n\nParticipants will:\n\n* Attend one routine dental appointment\n* Be randomly assigned to wear a VR headset or receive standard care during their procedure\n* Complete brief questionnaires about pain and anxiety before and after treatment\n* Receive a follow-up phone call 24-72 hours after the appointment",[84,27],"Dental Anxiety in Children",[86,87,88,89,90],"Distraction","Virtual reality","Pediatric Dentistry","Dental Anxiety","Procedural Pain","NOT_YET_RECRUITING","2026-06-30",{"date":63,"type":37},{"date":95,"type":21},"2026-06-02",{"date":97,"type":21},"2027-06-30",{"name":99,"class":44},"University of British Columbia",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":53,"sex":17,"minAge":77,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":45},"100643561","phase-1-a-study-to-evaluate-ibuprofen-ibu-625-mg-and-acetaminophen-apap-125-mg5-ml-in-an-oral-liquid-suspension-fixed-dose-combination-product-in-children-aged-6-to-11-years-100643561","NCT07632274","A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg\u002F5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years","A Phase I, Single-Center, Open-Label, Single-Dose, Pharmacokinetic Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg\u002F5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years","Inclusion Criteria:\n\n* Participants meeting at least one of the following criteria:\n\n  1. Participant with at least one acute, painful condition (e.g., minor aches and pains due to headache, menstruation, toothache, sports injuries, etc.) requiring use of an oral over the counter (OTC) analgesic within the previous 4 weeks (but not within the 48 hours prior to Day 1, Hour 0 investigational product dosing).\n  2. Participant has undergone a non-surgical orthodontic or dental procedure (e.g., placement of an orthodontic appliance or adjustment of braces) within 24 hours prior to dosing.\n  3. Participant with post-vaccination pain (post-injection site redness\u002Fsoreness, joint pain) and\u002For fever at time of investigational product dosing.\n  4. Participants who have a fever at time of investigational product dosing can be enrolled as long as the fever is low-grade (oral temperature less than (\\\u003C) 37.7 degree Celsius (°C) \u002F100.9 degrees Fahrenheit (ºF)) and, regardless of temperature, the fever has not lasted for more than (\\>) 48 hours as determined by the Investigator.\n* Participants except for medical condition(s) indicating the use of an OTC analgesic or post-immunization pain and\u002For fever, participants are in normal health as judged by the Investigator upon physical examination of the participant.\n* Participants\u002Fparent(s)\u002Flegal guardian who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n* Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and in this protocol. A personally signed and dated informed consent document indicates that the child's parent(s)\u002Flegal guardian has been informed of all pertinent aspects of the study.\n* Participants with evidence of a personally signed (printed name is acceptable) and dated assent document or verbal assent, indicating the participant is willing to participate in the study. If assent is evaluated not to be obtainable, age and maturity appropriate information should be given verbally to the participants, and the Investigator should document the discussion.\n* Participants who are within the 5th and 95th percentiles in physical growth characteristics (i.e., height and weight) by sex as described by the Center for Disease Control and Prevention (CDC) standard growth charts, and body mass index (BMI) based on age and sex.\n* Participants must have a total body weight between 48-95 lbs (21.8-43.1 kilogram (kg)).\n\nExclusion Criteria:\n\n* Participants with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).\n* Participants with any condition or history felt by the Investigator to place the child at risk.\n* Participants with history of angioedema and bronchospastic reactivity to aspirin or other non-steroidal anti-inflammatory drug (NSAID).\n* Participants with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients: Ibuprofen, or any other NSAID such as aspirin or naproxen, acetaminophen (paracetamol), or topical anesthetics (e.g., EMLA® cream).\n* Participants with use of antibiotic therapy within 14 days prior to Day 1.\n* Participants using the following:\n\n  1. Ibuprofen, or any other NSAID such as aspirin or naproxen, or acetaminophen (paracetamol) within 48 hours prior to dosing with investigational product.\n  2. Other prescription or nonprescription drugs within 2 weeks or 10 half-lives (whichever is longer) prior to dosing with investigational product.\n  3. Dietary and herbal supplements within 2 weeks prior to the first dose of investigational product and continuing through the last PK sample on Day 1.\n* Participants on treatment with an investigational drug within 90 days (or as determined by the local requirement) or 10 half-lives preceding the first dose of investigational product (whichever is longer).\n* Participants who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to signing the Informed Consent Form (ICF)\u002Fassent and\u002For during study participation.\n* Fever of greater than 38.3°C or if the participant is too ill to participate in the study, at screening and Day 1\u002FDay 1 of the study.\n* Screening supine systolic or diastolic blood pressure (BP) at or above the 90th percentile based on age and height percentiles (by sex) following at least 5 minutes of supine rest.\n* Participants with any laboratory result outside of the normal age-appropriate range that is judged by the Investigator to be clinically significant.\n* Participants with a positive urine drug screen.\n* Investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or Haleon employees, including their family members, directly involved in the conduct of the study.\n* Blood withdrawal as part of research or routine medical care, within 8 weeks of admission to the study site that would exceed 1.36 mL\u002Flbs per 8 weeks period, inclusive of medical care and planned sample collection for this study.\n* Participants with history of sensitivity to heparin or heparin-induced thrombocytopenia.\n* Participants with poor venous access.\n* Participants or participant parent(s)\u002Fguardians unwilling or unable to comply with the requirements of the protocol.\n* Participants who ate or drank grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos) from 2 weeks prior to dosing until collection of the final PK blood sample will be excluded as it could interfere with acetaminophen disposition.\n* Pregnant female participants of childbearing potential and at risk for pregnancy who are unwilling or unable to agree to an acceptable method of contraception for at least 5 weeks prior to the start of the trial, during the trial and for at least 30 days after the last dose of the investigational product.\n* Participants with history of substance abuse.","11 Years",{"count":109,"type":21},12,[111],"PHASE1","The purpose of this study will be to characterize the pharmacokinetic (PK) profile of the Fixed-Dose Combination (FDC) IBU 62.5 milligram (mg)\u002FAPAP 125 mg per 5 milliliter (mL) suspension in children 6 to 11 years of age, inclusive, to satisfy Pediatric Research Equity Act (PREA) requirements.",[27],"2026-06-29",{"date":92,"type":37},{"date":117,"type":37},"2026-06-19",{"date":119,"type":21},"2026-09",{"name":121,"class":122},"HALEON","INDUSTRY",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":45},"100644924","the-effect-of-a-stress-ball-during-oral-care-procedures-100644924","NCT07676422","The Effect of a Stress Ball During Oral Care Procedures","The Effect of a Stress Ball on Pain, Anxiety, and Stress During Oral Care Procedures: A Randomized Controlled Experimental Study","Inclusion Criteria:\n\n* Being 18 years of age or older,\n* Being conscious and able to communicate,\n* Having an indication for oral care application,\n* Agreeing to participate in the study voluntarily.\n\nExclusion Criteria:\n\n* Being under heavy sedation,\n* Those with limited upper extremity movement,\n* Those with severe neurological disorders,\n* Having any problem with squeezing a ball in their hand (wound, fracture, weakness)\n\nTermination Criteria:\n\n* Those who wish to withdraw from the study,\n* Those who change institutions\u002Fcity,\n* The study will be terminated in the event of the patient's death.",{"count":131,"type":21},52,[24],"This study aims to evaluate the effect of using stress balls during oral care procedures performed on conscious patients in the intensive care unit on patients' pain, anxiety, and stress levels.",[27,135],"Stress",[137,138],"Stress ball","Oral Care Procedures",{"date":92,"type":37},{"date":141,"type":37},"2026-05-25",{"date":143,"type":21},"2026-08-25",{"name":145,"class":44},"Yuzuncu Yil University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":45},"100640819","peloid-therapy-in-temporomandibular-joint-dysfunction-100640819","NCT07576582","Peloid Therapy in Temporomandibular Joint Dysfunction","The Effect of Peloid Therapy on Pain and Functional Outcomes in Patients With Temporomandibular Joint Dysfunction","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of temporomandibular joint dysfunction based on DC\u002FTMD criteria\n* Presence of TMJ-related pain for at least 4 weeks\n* Baseline pain intensity ≥3 on a 0-10 visual analog scale\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* History of temporomandibular joint trauma, tumor, active infection, or acute inflammation\n* Previous temporomandibular joint surgery\n* Presence of systemic inflammatory rheumatologic disease\n* Pregnancy\n* Open wound, active dermatitis, or skin condition preventing peloid application at the treatment site\n* Injection therapy (e.g., botulinum toxin) or regular physical therapy for TMJ within the past 3 months\n* Any clinical or behavioral condition that may interfere with study compliance",{"count":154,"type":21},40,[24],"This prospective, single-group clinical study will evaluate whether local peloid therapy improves pain and jaw function in adults with temporomandibular joint dysfunction. Participants will receive peloid therapy applied to the temporomandibular joint region and masticatory muscles for 20 minutes per session, 5 days per week, for 2 weeks. Pain and functional outcomes will be measured at baseline and at the end of treatment using validated clinical scales, including the Jaw Functional Limitation Scale-8, visual analog scale pain scores, Fonseca index, maximum mouth opening, and secondary otalgia assessment.",[158,27,159],"Temporomandibular Disorders (TMDs)","Otalgia",[161,162,163],"TMJ Disorders","pain","otalgia",{"date":63,"type":37},{"date":166,"type":37},"2026-04-01",{"date":168,"type":21},"2027-02-01",{"name":170,"class":44},"Uşak University",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":179,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":191,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":198,"locationsCount":45},"100645034","effect-of-virtual-reality-guided-imagery-on-pain-anxiety-and-fatigue-in-cancer-patients-undergoing-chemotherapy-100645034","NCT07677436","Effect of Virtual Reality-Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy","Effect of Virtual Reality Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","VRGI-Chemo Tri","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histologically confirmed breast cancer.\n* Stage I, II, or III breast cancer.\n* Underwent surgery as the initial treatment and are scheduled to receive the first cycle of adjuvant chemotherapy, with or without biologic therapy (e.g., AC or TC regimens).\n* Able to read, write, and communicate.\n* Able and willing to use a virtual reality headset.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Visual or hearing impairment that prevents the use of virtual reality.\n* Serious neurological or psychiatric disorders.\n* Current participation in other non-pharmacological interventions (e.g., meditation or relaxation therapy) that could influence the study outcomes.\n* Previous experience with virtual reality-guided imagery.\n* Use of analgesics, anxiolytics, or other medications during the intervention that may affect the study outcomes.","FEMALE",{"count":181,"type":21},108,[24],"This randomized controlled trial aims to evaluate the effectiveness of virtual reality-guided imagery in reducing pain, anxiety, and fatigue among female breast cancer patients undergoing adjuvant chemotherapy. Participants will be randomly assigned to either an intervention group receiving virtual reality-guided imagery in addition to routine care, or a control group receiving routine care",[185,186,187,188,27,189,190],"Virtual Reality","Guided Imagery","Breast Cancer","Chemotherapy","Anxiety","Fatigue",[192],"Virtual Reality, Guided Imagery , Breast Cancer, Chemotherapy , Pain, Anxiety , Fatigue","2026-06-27",{"date":92,"type":37},{"date":61,"type":21},{"date":197,"type":21},"2027-03",{"name":199,"class":44},"Thoalfokar Mohammed Al-Obaidi",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":216,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":45},"100490484","state-dependent-interoception-value-based-decision-making-and-introspection-100490484","NCT05666726","State-dependent Interoception, Value-based Decision-making, and Introspection","State-Dependent Interoception, Value-Based Decision Making, and Introspection","* INCLUSION CRITERIA:\n\nSubject selections will be equitable among those individuals who meet the inclusion criteria. Every effort will be made to balance sex and race. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* All sexes; Age 18 to 55.\n* Able to read and write in English to guarantee understanding of all written and spoken instructions, which are in English.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nFor all experiments:\n\n* Unable to comply with study procedures or follow-up visits\n* Has any serious or unstable medical condition or history that in a clinician s assessment implies a cardiovascular, neurological, or physical risk from the study procedures performed to induce negative valence states. This may include chronic systemic disorders that could worsen due to stress (e.g. uncontrolled hypertension, coronary artery disease for example a history of myocardial infarction or stable or unstable angina, or diabetes)\n* Has any current psychiatric diagnosis (based on SCID or the MINI Mini International Neuropsychiatric Interview) or no diagnosis but scores \\>=29 on Beck Depression Inventory II or \\>=26 on Beck Anxiety Inventory\n* Meets criteria for diagnosis of any substance-related or addictive disorder, or endorses any kind of problematic gambling behavior or problematic media-based addictive behavior (such as videogames, social-networking, online shopping, etc.)\n* Regular use of psychoactive medications or psychoactive substances\n* Regular use of corticosteroids\n* Is pregnant\n\nFor stress and pain induction:\n\n* Has a major medical condition or medical history that in a clinician s assessment could affect temperature sensitivity, pain thresholds, or ability to comply with study procedures. This may include cardiovascular, autonomic, neurological, psychiatric, or chronic systemic disorders (including but not limited to stroke, blindness, deafness, history of brain damage, neurodegenerative, neurotoxic or demyelinating disorder, or diabetes)\n* Has a medical condition that in a clinician s assessment might affect somatosensation (e.g., Raynaud s disease, peripheral neuropathy, or circulatory disorder)\n\nFor pain induction:\n\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)\n* Has a dermatological condition such as scars or burns, or has had a tattoo in the testing region within the previous 4 weeks that might influence cutaneous sensibility\n* Regular and recent use of prescription or over-the-counter medication that has a significant effect on pain or heat perception. These include medications such as centralacting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbiturates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an as needed basis is acceptable as long as the last dose taken was within 5 half-lives of testing.\n\nFor craving induction:\n\n* Has a condition that in a clinician s assessment could preclude the ability to hold 4-6 hours of fasting or that is associated with a risk of hypoglycemia (such as diabetes, kidney disease, insulinoma, adrenal or pituitary tumors or disorders, or anorexia nervosa)\n* Is currently engaged in any kind of diet medically- or self-prescribed or endorses a very strong desire to start a diet that involves eliminating or decreasing carbohydrate consumption\n* Has a history of food allergies such as tree-nut or peanut allergy.\n\nFor fMRI experiments:\n\n* Individuals with conditions that could pose a risk relating to the safety of the fMRI procedure but do not meet specific exclusion criteria for all experiments or for specific inductions will be excluded from the MRI portion of the protocol but may participate in the non-MRI sessions. Such conditions include:\n* Those with ferromagnetic metal in the cranial cavity or eye (e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body)\n* Those with an abnormality on a structural MRI\n* Those with an implanted cardiac pacemaker or auto-defibrillator\n* Those with an insulin pump\n* Those with an irremovable body piercing\n* Pregnancy (based on urine test completed within 24 hours prior to scan)\n* Left-handed (only for fMRI experiments involving thermal pain stimulation)","55 Years",{"count":209,"type":21},900,[24],"Background:\n\nNegative emotional states can affect a person s behavior as they make decisions. For example, hunger may make people more impatient; they may then make riskier choices. Other negative emotional states that can change behavior include stress, pain, and sadness. By learning more about how emotions affect thinking and behavior in healthy people, researchers hope to better understand how to identify and treat people with mental disorders.\n\nObjective:\n\nTo learn how negative emotions affect the brain and decision-making behavior.\n\nEligibility:\n\nHealthy people aged 18 to 55 years.\n\nDesign:\n\nParticipants will have 3 clinic visits in 3 weeks.\n\nParticipants will fill out questionnaires. They will be asked about their personal history, their personality, and state of mind.\n\nFor 2 visits, participants will be assigned to different groups. Each group will experience 1 type of emotional stressor:\n\nSome participants will watch a video.\n\nSome will have to do arithmetic problems.\n\nSome will have heat applied to an arm or leg.\n\nSome will experience cold by immersing their hand in ice water.\n\nFor a snack craving test, some will be tempted by food after a 4-hour fast.\n\nDuring these tests, participants will have sensors attached to their bodies. They will be videotaped. Saliva samples will be collected.\n\nAfter the stressors, participants will do tasks on a computer. They will need to make choices.\n\nSome participants will perform these decision-making tasks while lying in a brain scanner for functional magnetic resonance imaging. The brain scan involves lying on a table that slides into a cylinder that takes images of the brain.\n\n...",[135,27,213,214,215],"Emotions","Craving","Frustration",[217,218,219,135,27,220],"Decision-Making","Interoception","Metacognition","Negative Emotion",{"date":92,"type":37},{"date":223,"type":37},"2023-07-25",{"date":225,"type":21},"2029-12-31",{"name":227,"class":228},"National Institute of Mental Health (NIMH)","NIH",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":45},"100644014","a-study-of-the-impact-of-a-virtual-reality-medical-device-hypnovr-headset-on-anxiety-and-pain-in-interventional-radiology-100644014","NCT07668050","A Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.","HYPNO-VR","Inclusion Criteria :\n\n* Age ≥18 years.\n* Scheduled to undergo an interventional radiology procedure performed under local anesthesia without sedation.\n* Affiliation to a health insurance system.\n* Received complete information about the study and provided written informed consent.\n* Ability to understand the study information and complete the questionnaires.\n\nExclusion Criteria :\n\n* Refusal to participate or withdrawal of consent.\n* Patients under legal protection preventing valid informed consent according to regulatory requirements.\n* Inability to understand study-related information or to use the virtual reality device due to severe visual, auditory, or cognitive impairment, as clinically assessed by the investigator.\n* History of photosensitive epilepsy or uncontrolled epilepsy, constituting a contraindication to virtual reality use.\n* Known contraindication to virtual reality use (history of severe cybersickness).",{"count":237,"type":21},70,[24],"Patients undergoing interventional radiology procedures frequently experience significant anxiety and procedural pain despite standard care. Virtual reality (VR) has emerged as a promising non-pharmacological tool for anxiety and pain reduction in various medical settings.\n\nThe HYPNO-VR study is a prospective randomized controlled trial designed to evaluate the effect of immersive virtual reality during interventional radiology procedures. Participants will be randomized in a 1:1 ratio to either a virtual reality group or a standard care control group.\n\nThe primary objective is to assess the impact of VR on procedural anxiety and pain using validated anxiety questionnaires (State-Trait Anxiety Inventory, STAI) and a numerical pain rating scale.\n\nSecondary and exploratory objectives include assessment of patient satisfaction, operator experience, procedural duration, analgesic use, and feasibility of VR integration in interventional radiology practice.",[189,27,241],"Radiology, Interventional",[185,243,244,245,246,247,248,90],"Interventional Radiology","State-Trait Anxiety Inventory","Patient Satisfaction","Non-pharmacological Intervention","Immersive Virtual Reality","Procedural Anxiety","2026-06-25",{"date":114,"type":37},{"date":252,"type":21},"2026-06",{"date":254,"type":21},"2026-12",{"name":256,"class":44},"University Hospital, Clermont-Ferrand",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":272,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":45},"100613359","two-post-operative-pain-protocols-at-discharge-for-orthopaedic-patients-100613359","NCT07265557","Two Post-Operative Pain Protocols at Discharge for Orthopaedic Patients","A Pilot Randomized Controlled Trial Comparing Two Post-Operative Pain Protocols at Discharge for Orthopaedic Patients: A Pilot Study","Inclusion Criteria:\n\n1. Patients 18 years of age or older\n2. Underwent a major operative orthopaedic procedure\n\nExclusion Criteria:\n\n1. Contraindication for NSAIDs.\n2. Preoperative chronic opioid use (preoperative use of \\>14 days and average of \\>30 Morphine Milligram Equivalents per day).\n3. Active treatment for opioid use disorder.\n4. Previous or current illicit drug use.\n5. Major surgery for pathologic (cancer-related) condition.\n6. Hand surgery.\n7. Concurrent operative treatment by another specialty team.\n8. Discharged to an extended medical care facility.\n9. Incarceration.\n10. Women who are pregnant or planning to become pregnant in the next 6 weeks.\n11. Expected injury survival of less than 6 weeks.\n12. Terminal illness with expected survival of less than 6 weeks.\n13. Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.\n14. Currently enrolled in a trial that does not permit co-enrollment.\n15. Prior enrollment in the trial.\n16. Unable to obtain informed consent.\n17. Non-English speaking\n18. Eligible patient was not approached prior to hospital discharge (missed participant).\n19. Did not provide informed consent (declined participation).\n20. Other reason to exclude the patient, as approved by the Principal Investigator",{"count":265,"type":21},100,[24],"This is a single-center, pilot randomized controlled trial designed to evaluate the feasibility of a definitive trial comparing opioid-free discharge prescriptions to usual care (which includes opioids) in patients undergoing major orthopaedic surgery. The main objective is to inform the design and feasibility of the definitive RCT.",[269,270,27,271],"Orthopaedic Related Pain (Musculoskeletal Pain)","Opioid","Pilot Study",[270,273,274],"Pilot study","Musculoskeletal Pain","2026-06-23",{"date":249,"type":37},{"date":278,"type":37},"2025-10-06",{"date":280,"type":21},"2026-12-31",{"name":282,"class":44},"Massachusetts General Hospital",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":45},"100605079","the-efficacy-and-safety-of-pregabalin-and-mirogabalin-in-patients-with-fibromyalgia-100605079","NCT07157852","The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Mirogabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Newly diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\\[1\\]\n* Aged over 18 years old;\n* Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM;\n* Baseline numeric rating scale (NRS) score of 4 or higher;\n* Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range;\n* Estimated glomerular filtration rate (eGFR) of at least 30 mL\u002Fmin\u002F1.73 m²;\n* Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements;\n\nExclusion Criteria:\n\n* Previous allergic reactions to pregabalin, mirogabalin, or any of their excipients;\n* Prior diagnosis of epilepsy or depression requiring antidepressant therapy;\n* Women who are pregnant or breastfeeding;\n* Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment;\n* Suffering from acute or chronic pain disorders other than FM.",{"count":291,"type":21},674,[24],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Mirogabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or mirogabalin in treating FM, with the aim of providing a better treatment option for FM patients.",[295,296,297,27],"Fibromyalgia","Pregabalin","Mirogabalin",{"date":249,"type":37},{"date":300,"type":37},"2025-09-05",{"date":302,"type":21},"2027-08-31",{"name":304,"class":44},"Beijing Tiantan Hospital",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":320,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":45},"100644112","effect-of-ai-assisted-respiratory-training-on-pain-fatigue-and-respiratory-parameters-in-patients-after-open-heart-surgery-100644112","NCT07665593","Effect of AI-Assisted Respiratory Training on Pain, Fatigue and Respiratory Parameters in Patients After Open Heart Surgery","The Effect of Artificial Intelligence-Assisted Respiratory Training on Pain, Fatigue and Respiratory Parameters in Patients After Open Heart Surgery","Inclusion Criteria:\n\n* Patients undergoing elective open heart surgery.\n* Conscious.\n* Speaks and understands Turkish.\n* Has a chest tube inserted (on the right and\u002For left side).\n* No visual, auditory, or mental problems.\n* Willing to participate in the study.\n\nExclusion Criteria:\n\n* Undergoing concurrent other chest surgery or having a history of re-surgery.\n* Development of early postoperative complications (e.g., atelectasis) within 0-3 days.\n* Any loss of an extremity.\n* Long-term immobilization and intubation.\n* Development of severe post-surgery infections (such as mediastinitis or sepsis) or respiratory complications (such as pneumonia or atelectasis).",{"count":313,"type":21},111,[24],"This randomized controlled study aims to evaluate the effect of artificial intelligence (AI)-assisted respiratory training on fatigue, pain, and respiratory parameters in patients after open heart surgery.",[317,27,318,319],"Nursing Care","Breathing Exercises","Fatigue Recovery",[162,321,322,323,324],"nursing care","fatigue","breathing exercises","open heart surgery","2026-06-22",{"date":327,"type":37},"2026-06-24",{"date":329,"type":37},"2026-02-10",{"date":331,"type":21},"2026-10",{"name":333,"class":44},"Kocaeli University",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":45},"100535030","real-world-efficacy-of-evoke-closed-loop-spinal-cord-stimulation-cl-scs-therapy-in-chronic-pain-patients-ultra-100535030","NCT06246526","Real-World Efficacy of Evoke® Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Chronic Pain Patients (ULTRA).","ULTRA","Inclusion Criteria:\n\nBe 18 years of age or older at the time of enrollment.\n\nDiagnosed with chronic, intractable pain of the trunk and\u002For limbs, which has been refractory to conservative therapy for a minimum of 6 months.\n\nSubject has a minimum Visual Analog Scale (VAS) score of 60 mm or higher (where 100 mm indicates the worst imaginable pain) at baseline.\n\nBe an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n\nBe willing and capable of giving informed consent.\n\nBe willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\nSubject is pregnant or nursing.\n\nHave a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator.\n\nHave evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n\nHave an existing drug pump and\u002For SCS system or another active implantable device such as a pacemaker, deep brain stimulator (DBS), or sacral nerve stimulator (SNS).\n\nHave prior experience with SCS.\n\nBe concomitantly participating in another clinical study.",{"count":342,"type":21},50,[24],"This observational, prospective data collection is designed to evaluate the efficacy of CL-SCS therapy in real-world patients suffering from chronic pain.",[27,32,346],"Neuropathic Pain",[348,349],"Saluda","Spinal Cord Stimulation",{"date":275,"type":37},{"date":352,"type":37},"2024-01-30",{"date":354,"type":21},"2027-12-31",{"name":356,"class":44},"Saint Francis Hospital",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":45},"100305620","sociocultural--biobehavioral-influences-on-pain-expression-and-assessment-100305620","NCT03258580","Sociocultural & Biobehavioral Influences on Pain Expression and Assessment","* INCLUSION CRITERIA:\n\nAll Sub-Studies:\n\n* Healthy\n* Between 18 and 60 years old\n* Fluent in English\n* Able to provide written informed consent\n\nEXCLUSION CRITERIA:\n\nAll Sub-Studies:\n\n* Unable to comply with study procedures\n* Has a major-medical condition or medical history that in a clinician's assessment could affect ability to comply with study procedures, including neurological conditions (including stroke, blindness or deafness, or a history of brain damage)\n* Has a current mood disorder, anxiety disorder, or substance use disorder, or has a history of psychosis, hospitalization for a mental health condition, or recurrent psychiatric episodes.\n* NIH staff member who is a subordinate\u002Frelative\u002Fco-worker of any investigator on the protocol\n* Prior completion of a different sub-study within this protocol.\n* Is born outside of the states or territories of the United States of America\n* Does not currently reside in a state or territory of the United States of America\n\nSub-study 1:\n\n* Has a major-medical condition or medical history that in a clinician's assessment could affect heat sensitivity or pain thresholds. This may include cardiovascular, autonomic, or neurological conditions or a chronic systemic disease (e.g., diabetes)\n* Has a medical condition that in a clinician's assessment might affect somatosensation (e.g., Raynaud's disease, peripheral neuropathy, or circulatory disorder)\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)\n* Has a dermatological condition affecting the testing region, such as scars, burns, or recent tattoos that might influence cutaneous sensibility\n* Regular use of prescription medication that has a significant effect on pain or heat perception. Excluded medications include central-acting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbituates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an \"as needed\" basis is acceptable as long as the last dose was not taken was within 5 half-lives of testing.\n* Is left handed\n\nSub-study 4, FMRI participants:\n\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)\n* Is left-handed\n* Any FMRI contraindications, including:\n\n  * Ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body.\n  * Implanted cardiac pacemaker or auto-defibrillator.\n  * Insulin pump.\n  * Irremovable body piercing.\n* Pregnant women (based on urine test completed within 24 hours prior to scan).\n* Those with an abnormality on a structural MRI that has functional consequences based on clinician assessment.","60 Years",{"count":365,"type":21},700,[24],"Objective\n\nThe current proposal investigates behavioral, psychophysiological, and social processes that may help explain biases and disparate outcomes in pain. Health disparities, or health outcomes that adversely affect disadvantaged populations, are pervasive and apparent in many diseases and symptoms, including pain. Pain is the number one reason individuals seek medical treatment. Health disparities in pain encompass both differences in pain experience and treatment for pain. For instance, research indicates that Black individuals report increased pain and have reduced pain tolerance relative to White individuals, yet doctors are less likely to treat minority patients pain and underestimate their pain experience. This project aims to address this systemic discrepancy by focusing on interpersonal processes that may contribute to these disparities, including socially-relevant responses to pain (i.e. pain expression) and pain assessment (e.g. visual attention). The proposed research aims to determine whether the study of pain expressions and their assessment can yield insights on how social factors shape pain and its treatment. Further, we test the efficacy of potential interventions designed to improve accuracy and reduce biases in pain assessment. If successful, this work will form the foundation of a new research program that will link the field of pain research with the field of social neuroscience, and forge new insights on the critical problem of health disparities in pain.\n\nStudy population\n\nWe will accrue up to 700 total healthy volunteers to target 240 completers\n\nDesign\n\nOur overall aim is to understand how social factors influence the assessment and management of pain, and to gain insight into psychosocial processes that may underlie health disparities in pain. We propose a series of studies designed to test these links. First, we will measure pain perception and physiological responses to painful stimuli in a diverse group of individuals to test for sociocultural and biological influences on pain and pain-related responses. In subsequent studies, new participants (\"perceivers\") will view images of these initial participants (\"targets\") and will provide estimates of 'targets' pain experience. We will measure a) whether perceivers can accurately estimate 'targets' pain experience; b) whether accuracy differs as a function of similarity between target and perceiver (ingroup vs outgroup); and c) whether individuals can improve accuracy through feedback.\n\nOutcome measures\n\nPrimary outcome measures for all experiments will be decisions about pain (experienced by self or other) measured with visual analogue scales, reaction time, and\u002For categorical judgments (pain\u002Fno pain). We will also measure physiological responses (e.g., facial muscle response, skin conductance, pupil dilation) and brain responses using functional magnetic resonance imaging (fMRI) as secondary outcome measures. We will test whether pain and pain-related responses varies as a function of sociocultural\u002Fdemographic factors (e.g. race, ethnicity, sex) and whether accuracy in assessing others' pain is influenced by group similarity (i.e. ingroup vs. outgroup) and training (e.g. performance-related feedback)....",[369,370,27],"Normal Physiology","Healthy Volunteers",[27,372,373,374,375],"Visual Analogue Pain Scale","Healthy Volunteer","EYE TRACKING","Eye Movement",{"date":275,"type":37},{"date":378,"type":37},"2018-05-09",{"date":380,"type":21},"2027-05-30",{"name":382,"class":228},"National Center for Complementary and Integrative Health (NCCIH)",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":53,"sex":17,"minAge":390,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":395,"conditions":396,"keywords":399,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":45},"100641992","effects-of-music-therapy-in-chronic-neck-pain-100641992","NCT07658729","Effects of Music Therapy in Chronic Neck Pain","The Effects of Music Therapy on Pain, Cervical Position Sense, and Balance in Individuals With Chronic Neck Pain","Inclusion Criteria:\n\n* Being between 20-50 years old\n* Having experienced neck pain for at least 3 months\n* Having a resting neck pain score of 3 or higher on the Numeric Pain Scale\n* Being willing to participate in the study\n\nExclusion Criteria:\n\n* Patients with surgical indications for and\u002For who have undergone surgery in the cervical region\n* Having received physiotherapy and\u002For other treatment for neck pain within the last year\n* Those with a history of trauma and systemic disease in the cervical region (malignant condition, systemic rheumatic disease, etc.)\n* Having additional musculoskeletal diseases that may also affect the cervical region (thoracic outlet and scoliosis, etc.)\n* Having a psychiatric illness\n* Being visually impaired","20 Years","50 Years",{"count":393,"type":21},19,[24],"This study aims to investigate the effects of music therapy on pain, cervical position sense, and balance in individuals with chronic neck pain. Chronic neck pain is a common musculoskeletal disorder that may impair proprioception and postural control, negatively affecting daily functioning and quality of life. Music therapy is a safe, low-cost, and non-pharmacological intervention with potential benefits for pain management and sensorimotor function; however, evidence regarding its effects in musculoskeletal rehabilitation is limited. In this study, nineteen individuals with chronic neck pain will listen to instrumental Turkish Classical Music in the Nihavend mode for 60 minutes. Pain intensity, cervical position sense, and static and dynamic balance will be assessed before and after the intervention. The findings are expected to provide evidence for the clinical use of music therapy as an adjunctive treatment in chronic neck pain rehabilitation.",[397,27,398],"Neck Pain","Music Therapy",[400,401,402,403],"neck pain","music therapy","proprioception","balance","2026-06-18",{"date":275,"type":37},{"date":61,"type":21},{"date":408,"type":21},"2026-08-30",{"name":410,"class":44},"Karabuk University",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":428,"leadSponsor":430,"locationsCount":45},"100550088","pain-and-smoking-study---interactive-voice-response-100550088","NCT06442514","Pain and Smoking Study - Interactive Voice Response","Enhancing an Intervention for Smokers With Chronic Pain Using IVR: A Randomized Clinical Trial of Smoking Cessation Counseling for Veterans","PASS-IVR","Inclusion Criteria:\n\n* being an enrolled Veteran at VACHS;\n* current tobacco use;\n* willingness to make a quit attempt;\n* significant chronic pain defined as \\>\u002F=4 on the pain intensity portion of the Brief Pain Inventory (BPI) for more than 90 days.\n\nExclusion Criteria:\n\n* active diagnosis of dementia or psychosis in medical record;\n* severely impaired hearing or speech;\n* lack of telephone access;\n* enrollment in concurrent research study that might affect main outcomes of this study;\n* terminal illness;\n* non-English speaking;\n* pregnancy;\n* provider advising against exercise;\n* planned surgeries; and\n* clinically significant depressive symptoms (\\>10 PHQ-9).",{"count":420,"type":21},220,[24],"PASS2 aims to expand upon the recently completed study (PASS intervention), which tested the telephone delivery of a cognitive behavioral intervention (CBI). This study will use Interactive Voice Response (IVR) to optimize the intervention's effectiveness for smoking cessation among Veteran smokers with chronic pain.",[424,27,425],"Smoking","Smoking Cessation",{"date":275,"type":37},{"date":36,"type":21},{"date":429,"type":21},"2028-05-31",{"name":431,"class":432},"VA Office of Research and Development","FED",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":45},"100554409","phase-1-patient-controlled-administration-of-liquid-acetaminophen-100554409","NCT06498713","Patient Controlled Administration of Liquid Acetaminophen","Patient Controlled Self-Administration of Oral Liquid Medication: Acetaminophen Trial","Inclusion Criteria:\n\nParticipants\n\n* Adult patients older than 18 years old admitted to SRC for total shoulder and reverse total shoulder arthroplasty\n\nNurses\n\n* The nurse who will administer acetaminophen to a study patient.\n\nExclusion Criteria:\n\nParticipants\n\n* Pregnant patient\n* Patients that cannot swallow pills or cannot take liquid (for example due to risk of aspiration)\n* Emergency surgery\n* Chronic pain\n* On home opioids, any other pain modulating medications including benzodiazepine, Neurontin, ketamine.\n* Past medical or social history of substance abuse disorder, including ethanol misuse disorder, marijuana misuse disorder\n* History of any psychiatric disorders including anxiety, depression, any cognitive dysfunction\n* Any patients who cannot provide informed consents on their own (those who would need Legally Authorized Representatives (LARs) or surrogates)\n* Liver dysfunction limiting amount of safe oral acetaminophen\n* baseline hyperbilirubinemia (ex: chronic liver disease, Gilbert's)\n* patients unable to take PO\n* Patients with neurologic, neuromuscular, or movement disorders unable to drink from a cup.\n\nNurses\n\n* any nurse who is not involved in the direct care of a study patient, or who is not comfortable with setting up the PCA pump.",{"count":441,"type":21},24,[111],"This is a proof of concept pilot study investigating the feasibility and acceptability of patient controlled oral medication administration, using the commonly used and low risk medication in the hospital, oral acetaminophen.",[27,445],"Pain, Postoperative",[28],"2026-06-17",{"date":404,"type":37},{"date":450,"type":37},"2024-11-19",{"date":254,"type":21},{"name":453,"class":44},"Yale University",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":45},"100641446","use-of-hand-extension-rubber-during-intravenous-catheter-placement-100641446","NCT07659015","Use of Hand Extension Rubber During Intravenous Catheter Placement","The Effect of Hand Extension Rubber Used in Patients With Peripheral Intravenous Catheter Insertion on Pain, Anxiety and Satisfaction: A Randomized Controlled Trial","PIC","Inclusion Criteria:\n\n* Volunteers willing to participate in the study\n* Patients aged 18-65\n* Patients who are alert and able to communicate verbally in Turkish\n* Patients assigned to the green zone during triage\n* Patients suitable for PICC placement in the left cephalic and basilic veins\n* Patients who are right-handed\n* Patients with a VAS pain score of 0 prior to the PIC procedure\n\nExclusion Criteria:\n\n* Patients with acute or chronic pain\n* Patients with conditions that cause limited mobility, such as muscle disorders or grip dysfunction\n* Patients with peripheral neuropathy, arteriovenous fistula, or bilateral mastectomy\n* Patients with a psychiatric diagnosis (as self-reported)\n* Patients with communication impairments (hearing, speech, and vision)\n* Patients with a history of negative PIC procedure experiences\n\nTerminating Criteria:\n\n* Participants wishing to withdraw from the study at any stage after giving their consent\n* Failure of the PIC procedure\n* Failure to use the hand extension band until the end of the procedure\n* Occurrence of complications related to the PIC procedure during the procedure",{"count":463,"type":21},114,[24],"The study aims to investigate the effect of a hand extension rubber used in patients with peripheral intravenous catheters on pain, anxiety, and satisfaction.",[27,189,467],"Satisfaction",[469,470,460,27,189,467],"Nursing","Peripheral intravenous catheter","2026-06-15",{"date":325,"type":37},{"date":471,"type":21},{"date":475,"type":21},"2026-08-01",{"name":477,"class":44},"Necmettin Erbakan University",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":390,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":501,"leadSponsor":503,"locationsCount":45},"100643133","cervical-stabilization-exercises-in-subacromial-impingement-syndrome-100643133","NCT07645781","Cervical Stabilization Exercises IN Subacromial Impingement Syndrome","Efficacy Of Adding Cervical Stabilization Exercises To Conventional Physical Therapy In Subacromial Impingement Syndrome","CSEs in SIS","Inclusion Criteria:\n\n* Male and female patients with unilateral SIS.\n* Age is 20-40 years old.\n* Presence of pain on anterolateral aspect of the shoulder for at least three months.\n* At least 3 of the following criteria; positive Neer, Hawkins, and Empty can tests, Painful arc, and pain during resisted isometric abduction or external rotation.\n\nExclusion Criteria:\n\n* Shoulder surgery, injury and arthritis.\n* Any anatomical anomalies as hooked acromion.\n* Cervical radiculopathy.\n* Other systemic diseases: cardiovascular diseases, respiratory diseases and neurological diseases.","40 Years",{"count":488,"type":21},42,[24],"The goal of this clinical trial study is to determine efficacy of adding cervical stabilization exercises (CSEs) to conventional physical therapy (PT) program on pain severity, shoulder function disability, kinesiophobia, shoulder range of motion (ROM), isometric muscle strength and upper limb (UL) functional activity in closed kinetic chain in patients with SIS. The main questions it aims to answer is:\n\nWhat are the effects of adding cervical stabilization exercises to a conventional physical therapy program in the management of shoulder impingement syndrome? Researchers will compare two groups: one group will receive CSEs beside the conventional PT program to the another group will receive the conventional PT program.",[492,27],"Subacromial Impingement Syndrome",[494,495,496,497],"Subacromial impingement syndrome","Rotator cuff tendenitis","shoulder impingement syndrome","supraspinatus tendenitis",{"date":499,"type":37},"2026-06-16",{"date":61,"type":21},{"date":502,"type":21},"2027-09-01",{"name":504,"class":44},"Cairo University",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":512,"enrollmentInfo":513,"targetDuration":4,"studyType":22,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":45},"100628592","mindfulness-intervention-on-minimally-invasive-vascular-surgery-100628592","NCT07463638","Mindfulness Intervention on Minimally Invasive Vascular Surgery","Effect of Mindfulness Intervention Based on Virtual Reality Technology on Anxiety and Pain in Minimally Invasive Vascular Surgery Under Local Anesthesia: a Single-center, Prospective, Randomized Controlled Clinical Study","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. ASA physical status classification I-III.\n3. Diagnosis of superficial varicose veins confirmed by clinical examination and imaging studies (e.g., Doppler ultrasound, digital subtraction angiography), with documented venous insufficiency and great saphenous vein varicosity; CEAP classification grade 3-5.\n4. Scheduled for elective minimally invasive surgery for lower extremity varicose veins under local anesthesia.\n5. Voluntary participation in this study with signed informed consent.\n6. Able to cooperate with all examinations and follow-up visits required during the study.\n7. No other severe systemic diseases or surgical contraindications (e.g., severe cardiopulmonary dysfunction, coagulation abnormalities) that may compromise surgical safety or interpretation of study results.\n\nExclusion Criteria:\n\n1. Cognitive impairment (Mini-Mental State Examination \\[MMSE\\] score ≤26).\n2. Inability to wear VR equipment, or presence of sensory impairment (blindness or deafness).\n3. History of the same type of surgery.\n4. Presence of chronic or acute pain unrelated to peripheral vascular disease diagnosis.\n5. Oral opioid or nonsteroidal anti-inflammatory drug (NSAID) use within the past 30 days.\n6. Pregnancy or breastfeeding.\n7. Currently receiving or previously participated in psychological intervention.\n8. Prior mindfulness experience, documented history of psychiatric illness in medical records, or consultation with a trauma psychologist during the current hospitalization.","80 Years",{"count":514,"type":21},160,[24],"Background: Patients undergoing minimally invasive vascular surgery under local anesthesia often experience significant anxiety and pain, which may compromise surgical outcomes. Virtual reality (VR)-based mindfulness interventions may offer a novel approach to enhance the perioperative experience. Methods: This single-center, prospective randomized controlled trial will enroll 160 patients, randomly assigned in a 1:1 ratio to either the intervention group (VR mindfulness intervention) or the control group (standard care). Primary outcome: State trait anxiety scale (STAI-State) measures anxiety. Secondary outcomes: Numeric Rating Scale (NRS) for pain, vital signs, sleep quality, fatigue levels, satisfaction. Expected Results: VR mindfulness intervention is anticipated to significantly reduce anxiety and pain levels while improving sleep quality, fatigue levels, and patient satisfaction. Conclusion: As a safe, cost-effective, and immersive non-pharmacological intervention, VR mindfulness therapy holds promise for enhancing perioperative care quality.",[189,27],{"date":447,"type":37},{"date":520,"type":21},"2026-07",{"date":522,"type":21},"2027-01",{"name":524,"class":44},"Tongji Hospital",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":512,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":536,"conditions":537,"keywords":552,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":45},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)",{"count":534,"type":21},1859,[24],"The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[538,539,540,541,542,543,544,27,545,546,547,548,549,550,551],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[553,554,555,556],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold",{"date":447,"type":37},{"date":559,"type":37},"2026-06-11",{"date":561,"type":21},"2033-06",{"name":563,"class":122},"Teleflex",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":45},"100415119","virtual-reality-for-pain-management-in-burn-patients-100415119","NCT04685486","Virtual Reality for Pain Management in Burn Patients","Inclusion Criteria:\n\n* 8 years and older\n* Patients with a burn injury and is in the Burn Unit at New York Presbyterian\n* Awake, alert, ambulatory\n* The burn comprises less than 15% total body surface area (TBSA)\n* The patient does not require conscious sedation such as ketamine for staple removal or wound dressing changes\n* The patient is able to give informed consent\n\nExclusion Criteria:\n\n* Diagnosis of a cognitive disorder, psychotic disorder or bipolar I as determined by self-report from previous diagnosis\n* Current opioid abuse","8 Years",{"count":342,"type":21},[24],"This study is a randomized proof-of-concept study to assess the efficacy of Virtual Reality (VR) vs standard of care in 50 adult patients in the New York Presbyterian Burn Unit. The participants who are randomized to receive the virtual reality intervention will also receive opioids, which is the standard of care and is known to be effective. Participants will be randomly assigned to two groups. The first group will receive VR during their painful procedure (e.g., wound dressing changes, physical therapy etc.) in addition to the standard of care. The other group will receive standard of care (and no VR).",[27],[185,28,189,576],"Depression",{"date":447,"type":37},{"date":579,"type":37},"2018-06-01",{"date":581,"type":21},"2027-05",{"name":583,"class":44},"Weill Medical College of Cornell University",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":596,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":45},"100578511","therapy-dog-visits-for-patients-hospitalized-with-traumatic-injuries-100578511","NCT06812247","Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries","Inclusion Criteria:\n\n* Patients admitted to the Trauma and Acute Care Surgery (TACS) service following a trauma\n* English or Spanish speaking\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Fear of dogs, allergy to dogs\n* Immunocompromised\n* Contact precautions\n* Delirious, intubated, or otherwise unable to consent",{"count":80,"type":21},[24],"Animal assisted therapy (AAT) with dogs has been shown to be beneficial for a wide range of patients with both acute and chronic illnesses, including spinal cord injuries, heart failure, myocardial infarctions, strokes, cancer, post-traumatic stress disorder, and depression. Studies have also demonstrated that even in healthy adults, the presence of dogs is associated with physiologic changes such as increased pain threshold, decreased blood pressure, and decreased heart rate. However, few studies have investigated the role of AAT in the post-operative course in adults. This study will investigate the impact of therapy dog visits on pain and anxiety scores for trauma patients at Boston Medical Center (BMC).",[594,576,189,595,27],"Trauma Injury","Anger",[597,598,599,600],"Therapy dogs","Healing pups","Animal assisted therapy (AAT)","Traumatic injuries recovery","2026-06-13",{"date":499,"type":37},{"date":604,"type":37},"2025-06-04",{"date":254,"type":21},{"name":607,"class":44},"Boston Medical Center",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":614,"enrollmentInfo":615,"targetDuration":617,"studyType":57,"phases":4,"briefSummary":618,"conditions":619,"keywords":624,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":636},"100642258","registry-of-outcomes-of-dezawa-musecells-100642258","NCT07645989","Registry of Outcomes of Dezawa MuseCells®","Inclusion Criteria:\n\n1. Received Dezawa MuseCells® as Part of Routine Clinical Care\n2. Patients ( and\u002For authorized representative) capable of providing informed consent and participating in long-term follow-up.\n3. Willingness to Complete Online Survey Assessments\n4. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.\n5. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.\n6. Ability to Communicate in the Registry's Supported Language\n7. Participants must be able to read and respond to registry surveys in the designated study language.\n8. Enrollment Within 12 Months of MuseCell® Administration\n\nExclusion Criteria:\n\n1. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit\u002Fnon-licensed product cannot be included.\n2. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.\n3. Inability to Participate in Long-Term Digital Follow-Up\n4. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes\n5. History of Malignancy Diagnosed Within the Past 12 Months\n6. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.\n7. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality\n8. Use of Non-Licensed or Counterfeit \"Muse-like\" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.\n9. Pregnant or Actively Breastfeeding at Time of Enrollment","89 Years",{"count":616,"type":21},5000,"5 Years","The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.\n\nThe Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.",[620,621,622,27,623],"Osteoarthritis (OA)","Longevity","Wound Care","Orthopaedic",[625,626,162,627,628],"Muse Cells","stem cells","wound","inflammation",{"date":630,"type":37},"2026-06-12",{"date":61,"type":21},{"date":633,"type":21},"2031-12-31",{"name":635,"class":122},"MuseCell Innovations Pte LTD",2,{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":53,"sex":179,"minAge":18,"maxAge":644,"enrollmentInfo":645,"targetDuration":4,"studyType":22,"phases":647,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":656,"leadSponsor":658,"locationsCount":4},"100641838","the-effect-of-foot-reflexology-in-women-with-migraine-100641838","NCT07651839","The Effect of Foot Reflexology in Women With Migraine","The Effect of Foot Reflexology on Pain, Anxiety, Kinesiophobia, and Postural Control in Women With Migraine","Inclusion Criteria:\n\n* Being a woman between the ages of 18 and 45\n* Having been diagnosed with migraine by a neurologist according to the International Headache Society (IHS) criteria\n* Volunteering to participate in the study\n* Being literate\n* Not having entered menopause\n\nExclusion Criteria:\n\n* Having any neurological disease other than migraine\n* Having a psychiatric illness\n* Smoking\n* Having a musculoskeletal disease affecting the head and neck area\n* Having a history of cervical or cranial surgery\n* Having irritation or ulceration in the skin area to be massaged\n* Receiving migraine treatment other than pharmacological treatment (acupuncture, dry needling, cupping, etc.)\n* Having diabetic foot\n* Having open wounds on the foot\n* Pregnant individuals or individuals who become pregnant during the study period","45 Years",{"count":646,"type":21},20,[24],"This prospective randomized controlled study aims to investigate the effects of foot massage on pain, anxiety, kinesiophobia, and postural control in women aged 18-45 years diagnosed with migraine who attend the Neurology Outpatient Clinic of Karabük University Karabük Training and Research Hospital. Participants who meet the inclusion and exclusion criteria will be randomly allocated into either a foot massage group or a control group using a simple randomization method. The foot massage group will receive a total of 10 sessions of foot massage over 5 weeks, with two sessions per week, while no massage intervention will be applied to the control group. All participants will be assessed at baseline, immediately after the intervention period, and two weeks following the completion of treatment. The findings of this study are expected to provide evidence regarding the effectiveness of foot massage in the management of symptoms in women with migraine.",[650,651,27,189,652,653],"Migraine","Reflexology","Kinesiophobia","Postural Control",{"date":499,"type":37},{"date":404,"type":21},{"date":657,"type":21},"2026-07-30",{"name":410,"class":44}]